Re: Erdafitinib in BCG-treated High-risk Non–muscle-invasive Bladder Cancer
-
Published:2024-07
Issue:1
Volume:86
Page:74-75
-
ISSN:0302-2838
-
Container-title:European Urology
-
language:en
-
Short-container-title:European Urology
Author:
Duquesne IgorORCID,
de la Taille Alexandre
Reference5 articles.
1. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study;Balar;Lancet Oncol,2021
2. Multiparametric classification of non-muscle invasive papillary urothelial neoplasms: combining morphological, phenotypical, and molecular features for improved risk stratification;Montes-Mojarro;Int J Mol Sci,2022
3. Molecular markers increase precision of the European Association of Urology non-muscle-invasive bladder cancer progression risk groups;van Kessel;Clin Cancer Res,2018
4. KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC;Kamat;Future Oncol,2020
5. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients;Stein;J Clin Oncol,2001